Neumora Therapeutics (NMRA) Change in Account Payables (2022 - 2026)

Neumora Therapeutics has reported Change in Account Payables for 5 years, with the latest figure at $1.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables rose 174.41% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (up 845.62% YoY), and the FY2025 full-year result was $71000.0, down 97.53% from the prior year.
• Change in Account Payables for Q1 2026 stood at $1.7 million, down from $2.8 million in the prior quarter.
• The five-year high for Change in Account Payables was $7.0 million in Q2 2023, with the low at -$6.0 million in Q1 2023.
• Average Change in Account Payables over 5 years is $66571.4, with a median of -$252000.0 recorded in 2025.
• Year-over-year, Change in Account Payables surged 1542.16% in 2024 and plunged 295.24% in 2025.
• Tracing NMRA's Change in Account Payables over 5 years: stood at -$3.1 million in 2022, then jumped by 38.5% to -$1.9 million in 2023, then slumped by 51.52% to -$2.9 million in 2024, then jumped by 197.69% to $2.8 million in 2025, then plunged by 40.71% to $1.7 million in 2026.
• The last three Change in Account Payables figures came in at $1.7 million (Q1 2026), $2.8 million (Q4 2025), and -$96000.0 (Q3 2025), per Business Quant data.

Peer Comparison